Otsuka Holdings (TYO:4578) said its unit, Taiho Pharmaceutical, will acquire Swiss biotech firm Araris Biotech for up to $1.14 billion to strengthen its antibody-drug conjugate (ADC) pipeline, according to a Monday filing on the Tokyo Stock Exchange.
Taiho will pay $400 million upfront and potential additional milestone payments of up to $740 million. The deal is expected to close in the first half of 2025.
Price (JPY): $7712.00, Change: $+94, Percent Change: +1.23%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。